Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
July 31st, 2017
This protocol was developed to quantitatively identify tumor microenvironment components in glioblastoma patient resections using chromogenic immunohistochemistry and ImageJ.
The overall goal of this protocol is to quantitively identify tumor microenvironment components in glioblastoma patient resections using chromogenic immunohistochemistry and image J.This method can help answer key questions in the tumor microenvironment field, such as how these components look in patient samples and how we can determine physiologically relevant ratios of cells. The main advantage of this technique is that it is straightforward for analysis in patient samples. The implications of this technique extend toward elucidating the undercharacterized, complex glioblastoma tumor microenvironment.
Generally, individuals new to this method will struggle because timing for chromogenic development needs to be closely monitored to prevent overdevelopment and saturation of the tissue. Begin the protocol by performing the washes specified in the accompanying text protocol. Dilute tris-based high pH antigen unmasking solution and distilled water using the manufacturers recommendations.
Move on to heat mediated antigen retrieval by adding the diluted unmasking solution to a non-sealed microwaveable vessel. Place slides into the vessel. Then place the vessel slides into the microwave.
Next, boil the vessel for 20 minutes at high power. Monitor the liquid levels for evaporation and replenish the vessel with distilled water as necessary. Allow samples to cool in solution for one hour at room temperature.
Outline the tissue sample with a hydrophobic to minimize the volume of reagents necessary to cover the sample. Then, pipe in enough permeabilization solution, 100 to 200 microliters to cover the tissue sample. Remove and discard the solution and cover the tissue sample with permeabilization solution again.
Incubate the samples at room temperature with blocking solution for one hour. Then, incubate the samples overnight in four degrees Celsius with primary antibodies diluted in blocking solution. The next day, detect primary antibodies using a horseradish peroxidase polymer reagent corresponding with the primary antibody host animal.
Pipe in enough permeabilization solution to cover the tissue sample and incubate the sample for five minutes. Remove and discard solution and cover the tissue sample in permeabilization solution one more time for five minutes. Incubate the slides in 0.3%hydrogen peroxide and IX TBS for 15 minutes.
Develop the samples with a peroxidase diaminobenzidine or dab substrate for two to 10 minutes until the desired stain intensity is achieved. Counterstain the samples to identify cell nuclei, such as with hematoxylin following the manufacturers protocol. Dehydrate samples with 100%ethanol and xylene.
Finally, mount the samples permanently with mounting media. Two regions of interest within our tumor resections, the primary tumor Bulk and the Adjacent regions, primarily composed of healthy tissue with diffused invading cancer cells were identified by collaborating neuropathologist on hematoxylin and eosin stained patient samples. Chromogenic immunohistochemistry identified positive staining for astrocytes, microglia, and oligodendrocytes within each patient sample.
We performed staining with no primary antibody for a negative control. The manufacturer recommended and further dilutions before settling on the one to 200 dilution due to optimal positive staining of cell body and process with minimizing background for the anti ALDH 1l1 antibody. Using Image J, the percent coverage of OSP-1 positive oligodendrocyte staining was quantified to eventually compare differences in our regions of interest.
Once the appropriate threshold has been applied to the image, the percent coverage from the threshold can be measured and compared for multiple patients. Five adjacent and bulk regions of glioblastoma or GBM patient samples, along with healthy brain tissue were compared for oligodendrocyte-specific protein one or OSP1 percent coverage. Once mastered, the staining technique can be done in four hours on the first day and two hours the second day if it is performed properly.
While attempting this procedure, it's important to remember to closely monitor the tissue staining intensity and hydration.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol describes a method for quantitatively identifying tumor microenvironment components in glioblastoma patient resections using chromogenic immunohistochemistry and ImageJ. This technique aims to provide insights into the complex glioblastoma tumor microenvironment.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Histology
Background
- Glioblastoma is a highly aggressive brain tumor.
- The tumor microenvironment plays a crucial role in tumor progression.
- Understanding the composition of this environment is essential for developing targeted therapies.
- Chromogenic immunohistochemistry allows for detailed visualization of tissue components.
Purpose of Study
- To quantitatively assess the tumor microenvironment in glioblastoma samples.
- To determine physiologically relevant ratios of different cell types.
- To provide a straightforward analysis method for patient samples.
Methods Used
- Chromogenic immunohistochemistry for tissue staining.
- ImageJ software for quantitative analysis.
- Washing and antigen unmasking protocols as per manufacturer recommendations.
- Careful monitoring of chromogenic development timing.
Main Results
- Successful identification of various tumor microenvironment components.
- Establishment of methods for determining cell ratios in glioblastoma samples.
- Insights into the complexity of the glioblastoma microenvironment.
- Demonstration of the method's applicability to patient samples.
Conclusions
- This protocol provides a reliable method for studying glioblastoma microenvironments.
- It aids in understanding the interactions within the tumor microenvironment.
- Future research can build on these findings to improve glioblastoma treatment strategies.
Frequently Asked Questions
Executive Industry Relevance
Quantitative analysis of the tumor microenvironment in patient-derived glioblastoma samples enables mechanistic de-risking of glial cell targets in neuro-oncology drug discovery. By providing reproducible, region-specific measurements of astrocytes, microglia, and oligodendrocytes, this method supports target validation and phenotypic screening in disease-relevant systems. It enhances predictive confidence in preclinical models by linking microenvironment composition to therapeutic response and resistance mechanisms.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of glial cell phenotypes and their functional states within heterogeneous tumor regions.
- Operational Value: Provides quantitative, image-based readouts for assessing target engagement and microenvironment modulation.
- Predictive Value: Supports biomarker-aligned target selection by correlating glial abundance with pathological gradients in patient samples.
Screening & Assay Development
- Assay Readiness: Establishes standardized immunohistochemistry protocols compatible with high-throughput imaging and analysis pipelines.
- Quantitative Output: Delivers percent coverage metrics via ImageJ that enable inter-sample and inter-region comparisons.
- Reproducibility: Defines critical timing controls for chromogenic development to ensure signal specificity and minimize background noise.
Translational & Preclinical Research
- Disease Relevance: Uses actual patient resection samples to maintain pathophysiological fidelity in target validation studies.
- Translational Continuity: Bridges discovery findings to preclinical models by defining quantitative benchmarks for glial cell composition.
- Risk Mitigation: Reduces biological de-risking uncertainty in glial-targeted therapies by characterizing microenvironmental context.
Pipeline & Workflow Integration
This method fits within the discovery continuum from target hypothesis testing to lead optimization, particularly for neuro-oncology programs focused on microenvironment modulation.
- Discovery Biology: Supports mechanistic de-risking by enabling spatial and quantitative profiling of glial populations in human tissue.
- Screening: Generates standardized, quantifiable staining patterns that can be used to evaluate compound effects on microenvironmental composition.
- Analytics: Provides threshold-based percent coverage measurements that allow statistical comparison across experimental conditions.
- Translational Research: Aligns with biomarker strategies by linking glial cell densities to histopathological regions of interest.
- Enterprise Reuse: Establishes a transferable IHC/ImageJ workflow applicable across glioma and other CNS tumor models.
Operational & Enterprise Impact
- Scientific Value: Increases target confidence through quantitative, spatially resolved glial cell analysis in patient samples.
- Operational Value: Enhances reproducibility through standardized antigen retrieval, blocking, and development timing protocols.
- Strategic Value: Improves go/no-go decision-making by reducing ambiguity in target microenvironment interactions.
- Portfolio Impact: Enables risk-adjusted prioritization of glial-modulating therapeutics based on microenvironmental engagement data.
Implementation Considerations
- Requires expertise in immunohistochemistry and neuropathological sample handling.
- Dependent on optimized chromogenic development timing to avoid signal saturation.
- Necessitates standardized ImageJ thresholding protocols for consistent quantification.
- Requires access to patient-derived glioblastoma resection samples with annotated regions of interest.
- Limited by tissue heterogeneity and the need for region-specific analysis to avoid confounding signals.
